Back to UBS Group AG UBS Group AG

PVLAPVLA
7 quarters

Position history for UBS Group AGUBS Group AG's holdings in Palvella Therapeutics, Inc.

UBS Group AG holds 72,526 shares of PVLA (Palvella Therapeutics, Inc.), worth $11.1M as of 2026-Q2. The position was decreased (-30.6% shares). PVLA represents 0.0% of UBS Group AG's portfolio.

Current Value

$11.1M

Current Shares

72,526

Total Value Change

+$11.1M

Total Shares Change

+72,324

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
72,526
-30.6%
$11.1M0.0%$152.82
0
2026-Q1
Increased
104,537
+186.4%
$13M0.0%$131.51
45
2025-Q4
Increased
36,505
+78.6%
$3.8M0.0%$99.88
41
2025-Q3
Decreased
20,439
-52.6%
$1.3M0.0%$62.25
0
2025-Q2
Increased
43,149
+329.2%
$972,5790.0%$22.08
40
2025-Q1
Increased
10,054
+4877.2%
$281,4110.0%$28.10
38
2024-Q4
New
202
-
$2,4240.0%$12.00
19

Other major holders of PVLA: JENNISON ASSOCIATES LLC, BlackRock, Inc., STATE STREET CORP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used